Article

Bloodstream Infections Caused by Carbapenem-Resistant Pathogens in Intensive Care Units: Risk Factors Analysis and Proposal of a Prognostic Score

Giorgia Montrucchio 1,2,*, Andrea Costamagna 1,2, Tommaso Pierani 1,2, Alessandra Petitti 1,2, Gabriele Sales 1,2, Emanuele Pivetta 3, Silvia Corcione 4,5, Antonio Curtoni 6, Rossana Cavallo 6, Francesco Giuseppe De Rosa 4 and Luca Brazzi 1,2

1 Department of Surgical Sciences, University of Turin, 10126 Turin, Italy; andrea.costamagna@unito.it (A.C.); tommaso.pierani@gmail.com (T.F.); petitti.alessandra@libero.it (A.P.); g.sales@unito.it (G.S.); luca.brazzi@unito.it (L.B.)
2 Department of Anesthesia, Intensive Care and Emergency, Città Della Salute e Della Scienza di Torino University Hospital, 10126 Turin, Italy
3 Department of General and Specialized Medicine, Division of Emergency Medicine and High Dependency Unit, Città Della Salute e Della Scienza di Torino University Hospital, 10126 Turin, Italy; emanuele.pivetta@unito.it
4 Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy; silvia.corcione@unito.it (S.C.); francescogiuseppe.derosa@unito.it (F.G.D.R.)
5 Division of Geographic Medicine, Tufts University School of Medicine, 145 Harrison Ave, Boston, MA 02111, USA
6 Microbiology and Virology Unit, Città Della Salute e Della Scienza di Torino University Hospital, 10126 Turin, Italy; acurtoni@cittadellasalute.to.it (A.C.); rossana.cavallo@unito.it (R.C.)

*Correspondence: giorgiagiuseppina.montrucchio@unito.it

Abstract: Considering the growing prevalence of carbapenem-resistant Gram-negative bacteria (CR-GNB) bloodstream infection (BSI) in intensive care units (ICUs), the identification of specific risk factors and the development of a predictive model allowing for the early identification of patients at risk for CR-Klebsiella pneumoniae, Acinetobacter baumannii or Pseudomonas aeruginosa are essential. In this retrospective case–control study including all consecutive patients showing an episode of BSI in the ICUs of a university hospital in Italy in the period January–December 2016, patients with blood culture positive for CR-GNB pathogens and for any other bacteria were compared. A total of 106 patients and 158 episodes of BSI were identified. CR-GNBs induced BSI in 49 patients (46%) and 58 episodes (37%). Prognosis score and disease severity at admission, parenteral nutrition, cardiovascular surgery prior to admission to ICU, the presence of sepsis and septic shock, ventilation-associated pneumonia and colonization of the urinary or intestinal tract were statistically significant in the univariate analysis. The duration of ventilation and mortality at 28 days were significantly higher among CR-GNB cases. The prognostic model based on age, presence of sepsis, previous cardiovascular surgery prior to admission to ICU, the presence of sepsis and septic shock, ventilation-associated pneumonia and colonization of the urinary or intestinal tract were statistically significant in the univariate analysis. The duration of ventilation and mortality at 28 days were significantly higher among CR-GNB cases. The prognostic model based on age, presence of sepsis, previous cardiovascular surgery, SAPS II, rectal colonization and invasive respiratory infection from the same pathogen showed a C-index of 89.6%. The identified risk factors are in line with the international literature. The proposal prognostic model seems easy to use and shows excellent performance but requires further studies to be validated.

Keywords: carbapenem; multidrug resistance; antimicrobial resistance; Gram-negative bacteria; bloodstream infection; sepsis; risk factors; critically ill; intensive care

1. Introduction

Carbapenem-resistant Gram-negative bacteria (CR-GNB), including Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa, have spread alarmingly in recent years [1], leading to their inclusion in the World Health Organization (WHO) global critical
priority list of antibiotic-resistant bacteria [2]. These CR-GNB carry a risk of morbidity and mortality higher than their carbapenem-susceptible counterparts [3–6]. Bloodstream infections (BSI) due to carbapenem-resistant bacteria are usually diagnosed in subjects with severe underlying conditions, in the critically ill and/or in immunocompromised patients [7]. Isolates are generally resistant to first-line antibiotics resulting in a high rate of initial inappropriate therapy and/or leading to the use of less effective and more toxic drugs. This explains the frequent use of antibiotic combinations regimens with controversial results in terms of efficacy, toxicity and collateral environmental damage. Knowledge of local epidemiology, etiological distribution of causative agents and antibiotic resistance and factors associated with poor patient outcome are pivotal information to guide infection control and antimicrobial stewardship policies and to assist clinicians to choose the best therapeutic approach [8]. Other risk factors included the use of invasive devices and procedures, such as mechanical ventilation and catheterization, and exposure to the hospital environment, particularly the intensive care unit (ICU). Interventions to mitigate CR-GNB infections should target these factors [9].

The treatment of BSI caused by these strains is challenging due to their high morbidity and mortality rates [10,11]. In severe infections, with a high risk to evolve into septic shock, a delayed adequate antimicrobial therapy is associated with an increased mortality. The rapid identification of the aetiological agents of infection is essential for the administration of an early and appropriate antimicrobial therapy [12]. Unfortunately, the median time-to-positivity of blood cultures (BC) is frequently long, especially in patients with GNB BSI where it ranges from 5.9 to 49.8 h [13]. Although in recent years new microbiological assays have had to speed up the diagnostic process [14], additional time is necessary to obtain species identification and antimicrobial susceptibility test (AST) results [15]. For these reasons, clinical evaluation remains the milestone to ensure an early and appropriate initiation of empirical broad-spectrum antimicrobial therapy through the identification of those patients who have the highest risk of multidrug resistance, especially CR, BSI.

A growing number of experiences approached the development of scores based on patient risk factors, with the aim of the early recognition of patients eligible for an effective empirical therapy against the CR pathogens. In the different studies, specific pathogens, antimicrobial-resistance patterns and/or specific subpopulations of patients were considered [16–20]. Many studies have been conducted in Italy [21–23], a country characterized by one of the highest rates of resistance to antibiotics in Europe [24,25]. Unfortunately, despite the importance of this aspect, experiences with critically ill patients in ICU are limited [26,27]. With this premise, we decided to analyse a retrospective cohort of patients affected by BSI and recruited in five ICUs of a University Hospital in Italy with the aim of describing the current distribution of the epidemiological, etiological and susceptibility pattern of CR-GNB and to develop a risk-assessing tool to predict carbapenem-resistant aetiology in critically ill patients with BSI admitted in ICU.

2. Methods

2.1. Study Design

The present multicentric cohort study was conducted in five ICUs (general respiratory, emergency, cardiac surgical, post-surgical and neurosurgical) of the ‘Città della Salute e della Scienza’ University Hospital in Turin (Italy) between January 2016 and December 2016. Data were collected retrospectively and anonymously from medical records and from the laboratory information system by three investigators (T.P., A.P. and V.R.) and revised and checked by two senior investigators (G.M. and A.C.). The local Ethics Committee approved the study protocol (n. 0042680). Due to the retrospective nature of the study, written consent to participate was waived.
2.2. Subjects

All patients with at least one positive blood culture (BC) taken at least after 48 h after ICU admission were enrolled [28]. False positive blood culture, defined according to the ECDC criteria [29,30], were excluded.

Patients were divided into two groups: (1) CR-GNB group-patients developing at least one positive BC to CR-GNB belonging to the following species: *Klebsiella pneumoniae* and/or *Acinetobacter baumannii* and/or *Pseudomonas aeruginosa*. (2) Non-CR-GNB group-patients developing at least one positive BC to any pathogen other than those described for the CR-GNB group.

2.3. Variables Collected and Evaluated to Identify Potential Risk Factors

(1) Age and gender;
(2) Ward of initial admission, the occurrence of cardiovascular surgery before ICU admission, type of ICU;
(3) Prior antimicrobial therapy (ATB) therapy;
(4) ICU prognostic and clinical severity scoring systems at admission (APACHE score [31], SAPS II score [32], SOFA score [33], CHARLSON index [34]);
(5) Life support measures (mechanical ventilation, tracheostomy, extracorporeal life support, renal replacement therapy, parenteral nutrition, left ventricular assist device and pacemaker/internal cardioverter and defibrillator);
(6) BSI (central venous catheter site for BC positivity, number of BSI episodes);
(7) Laboratory tests at positive BC timepoint;
(8) Comorbidities: main diagnosis for ICU admission (i.e., any type of shock, cardiovascular, respiratory, abdominal or miscellaneous-other), sepsis or septic shock occurrence;
(9) Concurrent infection and/or colonization as potential BSI source: ventilator-associated pneumonia (VAP), ventilator-associated tracheobronchitis (VAT), urinary tract (UT) colonization, rectal colonization, central line-associated bloodstream infection (CLABSI).

2.4. Variables Collected to Describe Therapeutic Measures and Outcome

(1) Measures implemented after BSI evidence (i.e., CVC removal, empiric ATB match with antibiogram, need for proper ATB therapy switch after antibiogram evidence);
(2) Measures of outcome (i.e., ventilator-free days, ICU and in-hospital length of stay, in-hospital death and 28 days death).

2.5. Definitions

Resistance to carbapenem was defined, according to the Centers for Disease Control and Prevention (CDC), as follows:

− *K. pneumoniae*-defined as ‘carbapenem resistant’ when found resistant (R) to at least 1 of the following: imipenem, meropenem, doripenem, ertapenem;
− *P. aeruginosa* and *A. baumannii*-defined as ‘not susceptible to carbapenems’ when found to have an intermediate sensitivity (I) or to be resistant (R) to at least 1 of the following: imipenem, meropenem, doripenem.

A new manifestation of BSI due to the same pathogen was defined as a new positive BC after a 14-day course of effective ATB and in presence of clinical data and laboratory tests (leukocytes, C reactive protein and procalcitonin) compatible with the resolution of the infection and an effective source control [29]. Empirical therapy was defined as the administration of antibiotics before the availability of the sensitivity report. Appropriate empirical therapy was defined as a therapy containing at least one in vitro active drug (according to the susceptibility pattern of the isolate) administered within 24 h form the index BCs. Inappropriate empirical therapy was defined as inactive antibiotic administration or delayed antibiotic therapy. Definitive antibiotic therapy was defined as the antibiotic treatment administered according to susceptibility results. Duration of antibiotic treatment was defined as the number of consecutive days during which the patient received an appropriate antibiotic regimen. Source control was defined as performing any non-surgical
or surgical procedure to treat the infection source at any site including, among others, the urinary tract, biliary tract and surgical site, and the removal of any device deemed as the source of BSI within 7 days of index BCs.

2.6. Microbiology

Surveillance cultures are routinely performed at ICU admission and once a week and include tracheal aspirate, urinary cultures and rectal swab screening for CR-GNB.

Suspected GNB colonies grown on MacConkey II Agar (Becton–Dickinson, Franklin Lakes, NJ, USA) from tracheal and urinary cultures were identified and tested for CR using the semi-automated Microscan Walkaway 96 plus System (Beckman Coulter, Indianapolis, IN, USA) with Neg Combo 83 (Beckman Coulter) panels and a complete antimicrobial susceptibility test (AST) was provided. GNB isolated from rectal swab on selective solid media, Brilliance CRE AGAR (Oxoid, Basingstoke, UK), were identified by MALDI-TOF VITEK MS (bioMérieux, Marcy-l’Étoile, France) and CR was confirmed by meropenem and imipenem E-test (bioMérieux).

BCs are performed in case of clinical suspicion of infection. BCs were incubated using the automated BC system BACT/ALERT 3D (bioMérieux). Positive BC were processed according to the laboratory routine workflow as previously described [35]. Briefly, BC were seeded on the appropriate solid medium after Gram staining results (Columbia Agar with 5% Sheep Blood, MacConkey II Agar, Columbia CNA Agar with 5% Sheep Blood, Chocolate Agar, Becton–Dickinson, USA) and isolated colonies after overnight incubation were tested for identification and AST both on Microscan Walkaway 96 plus System (Beckman Coulter). The tested carbapenems minimum inhibitory concentrations (MIC) were 0.5–1 µg/mL for ertapenem, 1–8 µg/mL for imipenem, 0.12, 2, 8 µg/mL for meropenem with Neg Combo 83 (Beckman Coulter) panels and 0.002–32 µg/mL for both imipenem and meropenem with E-test (bioMérieux). For all tested antibiotics MIC values were interpreted according to the EUCAST clinical breakpoints. [36]

2.7. Endpoints

The primary endpoint was to develop a prognostic model capable of identifying, among the patients with positive blood cultures, those with BSI caused by CR-GNB species. Patients with BSI caused by CR-Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa were compared to those in whom BSI was due to susceptible bacteria. A logistic regression to identify predictive factors of CR bacteria was performed. A prognostic score for the risk of CR-GNB BSI was developed. The secondary endpoints were to evaluate the impact of CR-GNB BSI on patients’ outcomes.

2.8. Statistical Analysis

Descriptive data were tested for normal distribution by the Shapiro–Wilk test and presented as mean (±standard deviation [SD]) or median (with interquartile range [IQR]) as appropriate. Wilcoxon rank-sum test for unmatched samples was used for non-parametric continuous variables. Categorical variables were analysed with Chi-squared or Fisher’s exact test, as appropriate. All study variables showing a significant difference (p < 0.05) between CR-GNB and non-CR-GNB groups, were included in a univariate logistic regression to assess their role as risk factors for CR-GNB BSI. Multivariate logistic regression was performed using a selection of variables showing statistical significance at univariate analysis (p < 0.05). In the case of indicators described by different variables (severity upon admission to the ICU, presence of sepsis or septic shock, possible starting sources of BSI), the variable included in the model was that associated with a higher statistical value at the univariate. For the predictive score, the variables were selected according to international literature and univariate logistic models and combined in a prognostic model whose discrimination and calibration were assessed. Discrimination ability was measured using the C-index. Calibration was visually assessed by evaluating the predicted and observed the probability plot of infection after bootstrapping at 1000 replicates. Statistical analyses were
conducted using Stata 16.1/SE (Stata Corp TX, College Station, TX, USA) and R version 3.6.3 (The R Foundation for Statistical Computing, 2020).

3. Results

During the study period, data from 106 patients with BSI were collected, for a total of 158 BSI episodes. At least one blood culture positive for CR-GNB pathogens was identified in 49 (46%) patients. Overall, 76 (72%) patients had a single episode and 30 (29%) patients experienced multiple BSI episodes. Among the 30 patients experiencing multiple BSI episodes, 3 (6% of the total) presented BSI only from CR-GNB pathogens, 11 (19%) only from non-CR GNB pathogens and 16 patients (33%) presented different episodes caused by both non-CR GNB and CR GNB pathogens. The percentage of patients with multiple episodes was significantly higher among patients with at least one episode of CR-GNB BSI \((p = 0.026)\) (Figure 1; Tables 1 and 2). In CR-GNB group, registered MIC were always >32 \(\mu\)g/mL when confirmed by E-test (bioMérieux) methods.

![Microbiological isolates in the overall population. CR-GNB, Carbapenem-Resistant Gram-Negative Bacteria (n = 62); ESBL-GNB, Extended Spectrum Beta-Lactamase Gram-Negative Bacteria (n = 10); GNB, non-multi drug-resistant Gram-Negative Bacteria (n = 29); MR-GP, Methicillin-Resistant Gram-Positive Bacteria (n = 39); MS-GP, Methicillin-Sensitive Gram-Positive Bacteria (n = 34); Yeasts (n = 8).](image)

BSIs were caused in the CR group mostly by CR-\textit{K. pneumoniae} (49; 88%), followed by CR-\textit{A. baumannii} (4; 8%) and by CR-\textit{P. aeruginosa} (2; 4%).

Microbiological isolates (n = 182) are shown in Figure 1.

3.1. Baseline Characteristics and Risk Factors

There were not differences in age \((p = 0.7998)\) and gender \((p = 0.4260)\) in the study groups. APACHE \((p = 0.0121)\), SAPS II \((p = 0.0101)\) and SOFA \((p = 0.0305)\) scores at ICU admission were significantly higher in the CR-GNB group (Table 2).

The percentage of tracheostomized patients was higher in the CR-GNB group \((p = 0.0080)\) but the use of mechanical ventilation did not differ among groups \((p = 0.4930)\). Parenteral nutrition administration was significantly more frequent in the CR-GNB group \((p = 0.0280)\). No differences were observed neither in terms of the type \((p = 0.3790)\) for Carbapenem and \(p = 0.9120\) for Fluoroquinolone) nor in terms of the duration \((p = 0.6020)\) of antibiotic treatment before ICU admission.
Table 1. Microbiological isolates species in the overall population (182 isolates, from 158 episodes in 106 patients).

| Category | Species          | Number (Overall%) |
|----------|------------------|-------------------|
| CR-GNB   | K. pneumoniae    | 50 (27.5)         |
|          | A. baumannii     | 8 (4.4)           |
|          | P. aeruginosa    | 4 (2.2)           |
| ESBL-GNB | E. coli          | 7 (3.9)           |
|          | K. pneumoniae    | 1 (0.6)           |
|          | P. mirabilis     | 2 (1.1)           |
| GNB      | E. coli          | 1 (0.6)           |
|          | K. pneumoniae    | 1 (0.6)           |
|          | K. oxytoca       | 3 (1.7)           |
|          | E. aerogenes     | 1 (0.6)           |
|          | S. marcescens    | 7 (3.9)           |
|          | M. morganii      | 3 (1.7)           |
|          | P. aeruginosa    | 5 (2.8)           |
|          | S. maltophilia   | 1 (0.6)           |
|          | C. koseri        | 1 (0.6)           |
|          | H. alvei         | 1 (0.6)           |
|          | A. xylosidans    | 1 (0.6)           |
|          | E. cloacae       | 3 (1.7)           |
|          | A. baumannii     | 1 (0.6)           |
| MR-GP    | S. epidermidis   | 35 (19.2)         |
|          | S. aureus        | 2 (1.1)           |
|          | S. haemolyticus  | 2 (1.1)           |
| MS-GP    | E. faecalis      | 6 (3.3)           |
|          | E. faecium       | 8 (4.4)           |
|          | S. epidermidis   | 9 (5.0)           |
|          | S. aureus        | 4 (2.2)           |
|          | S. haemolyticus  | 1 (0.6)           |
|          | S. capitis       | 2 (1.1)           |
|          | S. simulans      | 1 (0.6)           |
|          | G. sanguinis     | 1 (0.6)           |
|          | S. cohnii        | 1 (0.6)           |
|          | B. casei         | 1 (0.6)           |
| Yeasts   | C. albicans      | 3 (1.7)           |
|          | C. glabrata      | 4 (2.2)           |
|          | C. parapsilosis  | 1 (0.6)           |
| Total    |                  | 182 (100)         |

List of abbreviations: CR-GNB, Carbapenem-Resistant Gram-Negative Bacteria; ESBL-GNB, Extended Spectrum Beta-Lactamase Gram-Negative Bacteria; GNB, non-multidrug-resistant Gram-Negative Bacteria; MR-GP, Methicillin-Resistant Gram-Positive Bacteria; MS-GP, Methicillin-Sensitive Gram-Positive Bacteria; Yeasts.

Most patients were admitted to ICU from a surgical ward (65; 59%). The CR-GNB group was characterized by a higher frequency of previous cardiac and/or vascular surgery (30; 61% vs. 22; 39%).

Sepsis ($p = 0.0010$) and septic shock ($p = 0.0450$) at ICU admission were most frequent in the CR-GNB group. While the rates of VAP ($p = 0.0020$), VAT (0.0030), urinary tract ($p = 0.0340$) and rectal colonization ($p < 0.001$) were significantly higher in the CR-GNB group, the incidence of CLABSI did not differ between groups ($p = 0.3570$).
Table 2. Baseline characteristics of patients and potential risk factors for CR-GNB BSI. List of abbreviations: CR-GNB, carbapenem-resistant Gram-negative bacteria; M, male; MV, mechanical ventilation; ECLS, Extra Corporeal Life Support; RRT, Renal Replacement Therapy; LVAD, Left Ventricular Assist Device; PM/ICD, Pacemaker/implantable cardioverter-defibrillator; BSI, Blood Stream Infection; CVC, Central Venous Catheter; CV, Cardiac and/or Vascular; PICC, Peripherally Inserted Central Catheter; VAP, Ventilator-Associated Pneumonia; VAT, Ventilator-Associated Tracheobronchitis; UT, Urinary Tract; CLABSIs, Central Line-associated Bloodstream Infection.

| Variable                                  | Non-CR-GNB (57) | CR-GNB (49)  | Total (106) | p-Value  |
|-------------------------------------------|-----------------|--------------|-------------|----------|
| **Demographics**                          |                 |              |             |          |
| Age (years)                               | 64 (55–73)      | 65 (53–73)   | 64 (54–73)  | 0.7998   |
| Gender M (N (%))                          | 38 (67%)        | 29 (59%)     | 67 (63%)    | 0.4260   |
| **ICU scoring systems**                   |                 |              |             |          |
| APACHE score                              | 15 (12–20)      | 19 (15–23)   | 18 (14–21)  | 0.0121   |
| SAPS II score                             | 39 (28–49)      | 46 (38–54)   | 42 (33–52)  | 0.0101   |
| SOFA admission                            | 8 (5–9)         | 9 (7–11)     | 8 (5–10)    | 0.0305   |
| CHARLSON index                            | 4 (2–6)         | 4 (3–6)      | 4 (3–6)     | 0.4239   |
| **Comorbidities**                         |                 |              |             |          |
| Main diagnosis                             |                 |              |             |          |
| Shock (N (%))                             | 19 (33%)        | 18 (37%)     | 37 (35%)    | 0.865    |
| Cardiovascular (N (%))                    | 7 (12%)         | 8 (16%)      | 15 (14%)    |          |
| Respiratory (N (%))                       | 18 (32%)        | 11 (23%)     | 29 (28%)    |          |
| Abdominal (N (%))                         | 7 (12%)         | 7 (14%)      | 14 (13%)    |          |
| Other (N (%))                             | 6 (11%)         | 5 (10%)      | 11 (10%)    |          |
| Sepsis (N (%))                            | 34 (60%)        | 43 (88%)     | 77 (73%)    | 0.0010   |
| Septic shock (N (%))                      | 16 (28%)        | 23 (47%)     | 39 (37%)    | 0.0450   |
| **Episodes of BSI**                       |                 |              |             |          |
| Single                                    | 46 (81%)        | 30 (61%)     | 76 (72%)    | 0.0260   |
| Multiple                                  | 11 (19%)        | 16 (33%)     | 27 (26%)    |          |
| **Potential source of BSI**               |                 |              |             |          |
| VAT (N (%))                               | 6 (11%)         | 17 (35%)     | 23 (22%)    | 0.0030   |
| UT colonization (N (%))                   | 3 (5%)          | 10 (20%)     | 13 (12%)    | 0.0340   |
| Rectal colonization (N (%))               | 3 (5%)          | 32 (65%)     | 35 (33%)    | 0.0000   |
| CLABSIs (N (%))                           | 46 (81%)        | 36 (74%)     | 82 (77%)    | 0.3570   |
| **Vital function support**                |                 |              |             |          |
| MV (N (%))                                | 46 (81%)        | 42 (86%)     | 88 (83%)    | 0.4930   |
| Tracheostomy (N (%))                      | 10 (18%)        | 20 (41%)     | 30 (30%)    | 0.0080   |
| ECLS (N (%))                              | 5 (9%)          | 10 (20%)     | 15 (14%)    | 0.1010   |
| ECLS (days)                               | 0 (0–0)         | 0 (0–0)      | 0 (0–0)     | 0.1471   |
| RRT (N (%))                               | 11 (19%)        | 14 (29%)     | 25 (24%)    | 0.2620   |
| RRT (days)                                | 0 (0–0)         | 0 (0–0)      | 0 (0–0)     | 0.2111   |
| Parenteral nutrition (N (%))              | 14 (25%)        | 22 (43%)     | 36 (34%)    | 0.0280   |
| LVAD (N (%))                              | 5 (9%)          | 5 (10%)      | 10 (9%)     | 1.0000   |
| PM/ICD (N (%))                            | 9 (16%)         | 7 (14%)      | 16 (15%)    | 0.8290   |
| **Prior ATB therapy**                     |                 |              |             |          |
| Duration of ATB therapy                   |                 |              |             |          |
| None                                      | 44 (77%)        | 35 (71%)     | 79 (75%)    | 0.602    |
| <7 days                                   | 6 (11%)         | 7 (14%)      | 13 (12%)    |          |
| 7–14 days                                 | 6 (11%)         | 4 (8%)       | 10 (9%)     |          |
| >14 days                                  | 1 (2%)          | 3 (6%)       | 4 (4%)      |          |
| Carbapenem before ICU admission (N (%))   | 6 (11%)         | 8 (16%)      | 14 (13%)    | 0.3790   |
| Fluoroquinolone before ICU admission (N (%)) | 10 (18%)  | 9 (18%)      | 19 (18%)    | 0.9120   |
3.2. Therapeutic Approach and Outcomes

There was no difference between the two groups either in the management of CVC \((p = 0.1510)\) or ATB revision \((p = 0.9150)\) after the BSI finding. A correspondence between the empiric ATB and the antibiogram indications emerged more frequently in the non-CR-GNB group \((p = 0.0080)\) (Table 3).

**Table 3.** Therapeutic intervention following BSI diagnosis and measures of outcome. List of abbreviations: CR-GNB, carbapenem-resistant Gram-negative bacteria; CVC, Central Venous Catheter; ATB, Antibiotic; LOS, Length of Stay.

| Variable               | Non-CR-GNB (57) | CR-GNB (49) | Total (106) | \(p\)-Value |
|------------------------|-----------------|-------------|-------------|-------------|
| **Therapeutic measures** |                 |             |             |             |
| CVC removal            |                 |             |             |             |
| None (N (%))           | 17 (30%)        | 21 (43%)    | 38 (36%)    | 0.151       |
| On suspicion (N (%))   | 22 (39%)        | 20 (41%)    | 42 (40%)    |             |
| On evidence (N (%))    | 18 (32%)        | 8 (16%)     | 26 (25%)    |             |
| ATB empiric Match (N (%)) | 27 (47%) | 11 (23%)    | 38 (36%)    | 0.0080      |
| ATB change             | 25 (44%)        | 22 (45%)    | 47 (44%)    | 0.9150      |
| **Measures of outcome** |                 |             |             |             |
| Ventilator free days   | 19 (0–25)       | 0 (0–4)     | 4 (0–22)    | 0.0000      |
| ICU LOS (days)         | 19 (8–37)       | 25 (13–44)  | 41 (11–40)  | 0.2631      |
| In-hospital LOS (days) | 42 (24–64)      | 47 (24–75)  | 44 (24–73)  | 0.5180      |
| Days before ICU        | 3 (1–13)        | 3 (0–16)    | 3 (0–15)    | 0.9083      |
| In-hospital death (N (%)) | 18 (32%) | 24 (49%)    | 42 (40%)    | 0.0680      |
| 28-day death (N (%))   | 10 (18%)        | 17 (35%)    | 27 (26%)    | 0.0430      |
| Death cause            |                 |             |             |             |
| Infection (N (%))      | 15 (88%)        | 17 (74%)    | 32 (80%)    | 0.263       |
| Other (N (%))          | 2 (12%)         | 6 (26%)     | 8 (20%)     |             |

Ventilator-free days were higher \((p < 0.001)\) in the non-CR-GNB group (19 (IQR: 0–25)) than in the CR-GNB group (0 (IQR: 0–4)). Even in the presence of a statistically non-different in-hospital mortality \((p = 0.0680)\) between the two groups (24 (49%) vs. 18 (32%)), the rate of 28-day mortality was statistically lower \((p = 0.0430)\) in the non-CR-GNB group (10; 18% vs. 17; 35%).

Infections were considered the leading cause of death either in the overall population (32; 80%) or in the two study groups (15; 88% non-CR-GNB vs. 17; 74% CR-GNB group, \(p = 0.2630)\).

3.3. Logistic Regression

Logistic regression model, in which five variables (SAPS II score, parenteral nutrition, cardio-vascular surgery before ICU, sepsis and rectal colonization) were included, highlighted that SAPS II score (OR 1.04, 95% CI 1.00–1.09), cardio-vascular surgery before ICU admission (OR 3.34, 95% CI 1.20–9.29) and rectal colonization (OR 10.58, 95% CI 3.59–31.55) are all factors statistically associated with BSI from CR-GNB (Table 4).

3.4. Prognostic Model

The prognostic model was realized using the following variables defined on the basis of literature, clinical experience and data obtained from the univariate model: age, presence of sepsis, previous cardiovascular surgery in the same hospital, the SAPS II score, rectal colonization by the same pathogen, invasive respiratory infection by the same pathogen. The prognostic nomogram and the calibration of the model (C-index 0.896) are shown in Figures 2 and 3.
Table 4. Uni- and Multi-variate logistic regressions of risk factors for CR-GNB aetiology for BSI. List of abbreviations: CR-GNB, carbapenem-resistant Gram-negative bacteria; CV, Cardiac and/or Vascular; ICU, Intensive Care Unit; VAP, Ventilator-Associated Pneumonia; VAT, Ventilator-Associated Tracheobronchitis; UT, Urinary Tract.

| Dependent Variable | Independent Variables | Univariate | Multivariate |
|--------------------|-----------------------|------------|--------------|
| CR-GNB-BSI+        | APACHE score          | 1.09 0.04 2.37 1.02–1.17 0.018 | 1.04 0.02 2.06 1.00–1.09 0.039 |
|                    | SAPS II score         | 1.04 0.02 2.50 1.01–1.08 0.012 | 1.04 0.02 2.06 1.00–1.09 0.039 |
|                    | SOFA admission        | 1.14 0.07 2.14 1.01–1.29 0.033 | 1.14 0.60 0.24 0.40–3.22 0.808 |
|                    | Parenteral nutrition  | 2.50 1.05 2.18 1.10–5.71 0.029 | 1.14 0.60 0.24 0.40–3.22 0.808 |
|                    | CV surgery before ICU admission | 2.44 0.98 2.22 1.11–5.36 0.026 | 3.34 1.74 2.30 1.20–9.29 0.021 |
|                    | Sepsis                | 4.84 2.49 3.08 1.78–13.24 0.002 | 1.97 1.29 1.03 0.54–7.13 0.302 |
|                    | Septic shock          | 2.27 0.93 1.99 1.01–5.07 0.046 |                     |
|                    | VAP                   | 4.52 2.26 3.03 1.70–12.03 0.002 |                     |
|                    | VAT                   | 4.52 2.37 2.87 1.61–12.65 0.004 |                     |
|                    | UT colonization       | 4.62 3.19 2.21 1.19–17.88 0.027 |                     |
|                    | Gastro-intestinal colonization | 33.88 22.52 5.30 9.21–124.69 0.000 | 10.58 5.90 4.23 3.59–31.55 0.000 |
Figure 2. Nomogram for predicting risk of developing CR-GNB BSI. Points are summed for each risk factor. List of abbreviations: CR-GNB, Carbapenem-Resistant Gram-Negative Bacteria; CV, Cardiac and/or Vascular; GI, gastro-intestinal; VAP, Ventilator-Associated Pneumonia.

Figure 3. Calibration curves for the prognostic model. List of abbreviations: CR-GNB, Carbapenem-Resistant Gram-negative Bacteria.

Figure 2 is the nomogram built using the variables included in the model. Their presence or absence allow an overall probability of developing CR-GNB BSI to be obtained. Such a model has been calibrated based on a 1000-repetition bootstrap process (see Methods), and Figure 3 shows the results of it. The prediction model has some divergences from the ideal prediction (i.e., the dotted line) but their entity is negligible at about 40% and 90% probability of CR-GNB BSI.
4. Discussion

Our data show that in a high rate of cases (46%) the aetiologic agents of BSI are CR-GNB as confirmed by the international literature, where the growing impact of Gram-negative aetiology in BSI is reported to be around 50% [37]. More in detail, it appears that around 80% of the cases are attributable to *K. pneumoniae*, 8% to *A. baumannii* and 4% to *P. aeruginosa*. In Italy, *E. coli*, *K. pneumoniae*, *P. aeruginosa* and *A. baumannii* together constitute 73% of BSI agents and carbapenem resistance rate is 13.1% in GNB-BSI and 16.7% in hospital acquired infections [38,39].

In our cohort, among invasive infections, *K. pneumoniae* was the most frequent CR-GNB (22.6% of isolated, carbapenem resistance rate of 37%), followed by *A. baumannii* (7.1% of all isolated, but with resistance rate to carbapenems of 79.9%) and *P. aeruginosa* (12.4% of all isolated, carbapenem resistance rate of 28%). It is worth noting that the population enrolled in our cohort is relatively young and is characterized by a high clinical severity, as demonstrated by the prognostic score values. The APACHE II, SAPS II and SOFA scores calculated at ICU admission were significantly higher among CR-GNB cases, confirming that this aetiology mainly affects critically ill patients [9,40].

An interesting observation is that the CR-GNB group is characterized by a higher percentage of patients undergoing cardiac or vascular surgery in the 30 days prior to ICU admission (61% vs. 39% of the control group), suggesting a possible role of surgery in predicting the occurrence of CR-GNB aetiology, in line with previous studies [22,41,42].

Other sources of potentially BSI-associated infections included ventilator-associated pneumonia (VAP), ventilator-associated tracheobronchitis (VAT), urinary tract and gastrointestinal colonization which were all significantly more frequent among CR-GNB group (VAP 38.8% vs. 12.3%-VAT 35% vs. 11%). This data is also in line with the literature, where respiratory infections are reported as the most common source of pathogen isolation non-susceptible to carbapenems [37,43].

Our data support the hypothesis that CR-GNB carriage status is strongly associated with the risk of BSI. In the multivariate analysis, gastrointestinal colonization was confirmed to be a strong independent risk factor for CR-GNB BSI (OR of 10.58, 95% CI 3.59–31.55). This is consistent with literature evidence that intestinal colonization by CRE is a significant risk factor for the development of invasive infection in critically ill patients admitted to ICU [20,40,44,45]. *P. aeruginosa* also frequently colonizes the gut of hospitalized patients and its colonization is a significant risk factor for the development of infection, as well as for *A. baumannii* [46–48].

With regard to previous antibiotic therapies, there was no correlation between the duration of antimicrobial therapy, nor between the administration of antibiotics known to select more resistances, such as carbapenems or fluoroquinolones, and the carbapenem-resistant BSI.

Inappropriate empiric antibiotic therapy was administered more frequently in the group of patients with CR-GNB BSI, since 77% of these patients received a therapy that did not contain any of the active antibiotics according to the antibiogram, compared to the 53% in non-CR-GNB controls. This is also in line with other studies where inappropriate empiric antibiotic therapy is prescribed up to 70% of cases of multidrug-resistant bacteria, and it is recognized as one of the risk factors for mortality [39,49–51].

CR-GNB patients were treated with mechanical ventilation for a longer period. This can be interpreted as a sign of severity on the admission and of the greater impact of the infection. Always in line with the literature, sepsis and septic shock were in fact present, respectively, in 88% and 47% of CR-GNB patients compared to 60% and 28% of controls [52].

Overall, 28-day mortality was 25%, but it reached approximately 35% among patients who developed CR-GNB infection. The data confirmed the known higher mortality associated with CR-aetiology than the one compared to that due to susceptible Gram-negative infections, whose frequency varies from 30% to more than 70% [20,22,40,49,52].

Specific predictors of CR-aetiology in critically ill ICU patients with BSI, such as SAPS II score, cardio-vascular surgery before ICU admission, gastro-intestinal colonization, were
identified. These factors were combined with literature findings and weighted to develop a simple tool to be used by clinicians to estimate the probability of CR-GNB aetiology in patients with suspected BSI. Each considered variable (age, presence of sepsis, previous cardio-vascular surgery in the same admission, SAPS II, gastro-intestinal colonization or invasive respiratory infection by the same pathogen) corresponds to a specific relative risk score that can be combined with the others, based on the patient’s characteristics, in a well-calibrated model (C-index = 89.6%).

Several scores have been proposed in order to estimate the risk of developing infections by multi-resistant pathogens [18, 19, 22, 26, 27, 37]. However, these scores were focused either on different settings from ICU, or not only on BSI or on specific subgroups of patients. For instance, Giannella et al. [19, 20] investigated the risk in liver transplant recipients colonized with carbapenem-resistant Enterobacteriaceae; Tumbarello et al. [22] identified risk factors specifically associated with K.pneumoniae KPC infection—regardless on the site—in all hospitalized patients, while Vadesuvan et al. [26] proposed a simple but effective score to predict nosocomial resistant Gram-Negative Bacilli infections among ICU patients, already validated in an external cohort [27].

It is clear that the purpose of a score is the early identification of patients requiring an empirical therapy capable of covering CR-pathogens. As previously underlined, ensuring an adequate early antibiotic therapy is necessary especially in the context of ICU patients; it is equally important to limit the use of broad-spectrum antibiotics as much as possible, as recommended by the antimicrobial stewardship programs [53, 54]. In addition, the times for returning the microbiological results differ strongly from centre to centre, especially on the basis of the routinely used diagnostic techniques. Despite the recent introduction of rapid techniques to recognize the BSIs, such as MALDI-TOF or other molecular methods, which allow for the rapid identification of the microbial species and their principal resistance genes on the day of BC positivity [14], the time-to-results remains a critical issue mostly for complete antimicrobial susceptibility test reports.

Considering all those issues, it is essential to define on the basis of the risk factors, the recent history and the current clinical presentation—which patients should be referred to a so-called “pre-emptive” therapy against CR-pathogens [39, 42]. The proposed score seems to have a good calibration on the studied cohort. A low risk according to our score can reassure the clinician of the lack of need for such coverage; conversely, a higher score—as defined by the likely CR-GNBs isolation in blood culture—can lead to considering a CR-covering antimicrobial therapy earlier (ideally, at the time of blood culture). Since the delayed administration of an effective antibiotic therapy is the strongest predictor of poor survival outcomes [55], a tool facilitating an early adequate therapy becomes essential for the clinician.

Limits

Our study has limitations. First, it is a retrospective study and recent, rapidly evolving scenarios might have changed the situation, especially considering the pandemic and the introduction of new antibiotics for multi-resistant pathogens. Moreover, the retrospective nature of the study did not allow us to properly assess the percentage of BSIs related to the presence of a central venous catheter, which is important data in the ICU setting. Another limiting factor is that the microbiology ecology may be shaped by local issues and the results could be influenced by the epidemiology of a restricted area of our country, even if we analysed a cohort of patients from five different ICUs. Additionally, our cohort of patients is from large tertiary teaching hospitals reflecting the complexity and epidemiology of patients managed in similar institutions. Italy is a country with a high prevalence of multidrug-resistant organisms, and our findings cannot be generalized to other countries with a lower prevalence of antibiotic resistance. Regarding the impact of previous antimicrobial use on the possibility to develop CR-GNB strains, although neither carbapenems nor fluoroquinolones seem to play a causative role, it was not possible to fully collect data on
other antibiotic therapies. Finally, the number of BSI episodes due to CR-GNB strains was relatively small.

5. Conclusions

About a half of the patients enrolled in our study developed CR-GNB BSI, in clear superiority if compared to the literature and with a strong impact on patient survival, as these pathogens were associated with higher mortality and lower efficacy of initial empirical therapy. Specific risk factors—clinical severity of the patients, presence of sepsis, concomitance of respiratory infections and gastrointestinal colonization—are in line with the literature.

Our clinical easy, fast-performing prediction tool could enable a better targeting of the early antimicrobial treatment for BSI, maintaining an antimicrobial stewardship perspective in the ICU context with its elevated incidence of CR resistance.

Further multicentric and prospective studies are needed to confirm our data and to validate the model and better define the impact of each risk factor.

Author Contributions: Conceptualization, G.M., A.C. (Andrea Costamagna), E.P. and S.C.; methodology, G.M., A.C. (Andrea Costamagna), E.P., A.C. (Antonio Curtoni) and S.C.; software, A.C. (Andrea Costamagna) and E.P.; validation, A.C. (Andrea Costamagna) and E.P.; formal analysis, A.C. (Andrea Costamagna) and E.P.; investigation, G.M., T.P., A.P. and G.S.; resources, L.B., F.G.D.R. and R.C.; data curation, G.M., A.C. (Andrea Costamagna), T.P., A.P., G.S. and A.C. (Antonio Curtoni); writing—original draft preparation, G.M. and A.C. (Andrea Costamagna); writing—review and editing, G.M., A.C. (Andrea Costamagna), G.S., A.C. (Antonio Curtoni), S.C., R.C., F.G.D.R. and L.B.; supervision, F.G.D.R. and L.B.; project administration, G.M., A.C. (Andrea Costamagna) and A.C. (Antonio Curtoni). All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki. The local Ethics Committee of Città della Salute e della Scienza Hospital approved the study protocol (n. 0042680).

Informed Consent Statement: Patient consent to participate was waived according to local Ethics Committee due to the retrospective nature of the study.

Data Availability Statement: Data are available upon reasonable request to the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Lodise, T.P.; Bassetti, M.; Ferrer, R.; Naas, T.; Niki, Y.; Paterson, D.L.; Zeitlinger, M.; Echols, R. All-Cause Mortality Rates in Adults with Carbapenem-Resistant Gram-Negative Bacterial Infections: A Comprehensive Review of Pathogen-Focused, Prospective, Randomized, Interventional Clinical Studies. Expert Rev. Anti Infect. Ther. 2022, 20, 707–719. [CrossRef] [PubMed]

2. WHO. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Available online: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (accessed on 6 June 2022).

3. Lemos, E.V.; de la Hoz, E.P.; Einaron, T.R.; McGhan, W.F.; Quevedo, E.; Castañeda, C.; Kawai, K. Carbapenem Resistance and Mortality in Patients with Acinetobacter baumannii Infection: Systematic Review and Meta-Analysis. Clin. Microbiol. Infect. 2014, 20, 416–423. [CrossRef] [PubMed]

4. Falagas, M.E.; Lourida, P.; Poulikakos, P.; Rafailidis, P.I.; Tansarli, G.S. Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence. Antimicrob. Agents Chemother. 2014, 58, 654–663. [CrossRef] [PubMed]

5. Cai, B.; Echols, R.; Magee, G.; Arjona Ferreira, J.C.; Morgan, G.; Ariyasu, M.; Sawada, T.; Nagata, T.D. Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. In Open Forum Infectious Diseases; Oxford University Press: Oxford, UK, 2017; Volume 4. [CrossRef]

6. Maroalo, A.E.; Corcione, S.; Grossi, A.; Signori, A.; Alicino, C.; Hussein, K.; Trecarichi, E.M.; Viale, P.; Timsit, J.-F.; Veeraraghavan, B.; et al. The Impact of Carbapenem Resistance on Mortality in Patients with Klebsiella pneumoniae Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 Patients. Infect. Dis. Ther. 2021, 10, 541–558. [CrossRef]
Pathogens 2022, 11, 718

7. Pascale, R.; Corcione, S.; Bussini, L.; Pancaldi, L.; Giacobbe, D.R.; Ambretti, S.; Lupia, T.; Costa, C.; Marchese, A.; De Rosa, F.G.; et al. Non-Fermentative Gram-Negative Bloodstream Infection in Northern Italy: A Multicenter Cohort Study. BMC Infect. Dis. 2021, 21, 806. [CrossRef]

8. Gniadek, T.J.; Carroll, K.C.; Siminer, P.J. Carbapenem-Resistant Non-Glucose-Fermenting Gram-Negative Bacilli: The Missing Piece to the Puzzle. J. Clin. Microbiol. 2016, 54, 1700–1710. [CrossRef]

9. Palacios-Baena, Z.R.; Giannella, M.; Manissero, D.; Rodriguez-Baño, J.; Viale, P.; Lopes, S.; Wilson, K.; McCool, R.; Longshaw, C. Risk Factors for Carbapenem-Resistant Gram-Negative Bacterial Infections: A Systematic Review. Clin. Microbiol. Infect. 2021, 27, 228–235. [CrossRef]

10. Falcone, M.; Russo, A.; Iacovelli, A.; Restuccia, G.; Cecarelli, G.; Giordano, A.; Farcomeni, A.; Morelli, A.; Venditti, M. Predictors of Outcome in ICU Patients with Septic Shock Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae. Clin. Microbiol. Infect. 2016, 22, 444–450. [CrossRef]

11. Tzouvelekis, L.S.; Markogiannakis, A.; Piperaki, E.; Souli, M.; Daikos, G.L. Treating Infections Caused by Carbapenemase-Producing Enterobacteriaceae. Clin. Microbiol. Infect. 2014, 20, 862–872. [CrossRef]

12. Lodise, T.P.; Patel, N.; Kwa, A.; Graves, J.; Furuno, J.P.; Graffunder, E.; Lomaestro, B.; McGregor, J.C. Predictors of 30-Day Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: Impact of Delayed Appropriate Antibiotic Selection. Antimicrob. Agents Chemother. 2007, 51, 3510–3515. [CrossRef]

13. Palmer, H.; Palavecino, E.; Johnson, J.; Ohl, C.; Williamson, J. Clinical and Microbiological Implications of Time-to-Positivity of Blood Cultures in Patients with Gram-Negative Bacilli Bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 2013, 32, 955–959. [CrossRef]

14. Sanguinetti, M.; Posteraro, B. Mass Spectrometry Applications in Microbiology beyond Microbe Identification: Progress and Potential. Expert Rev. Proteom. 2016, 13, 965–977. [CrossRef]

15. Chen, J.-R.; Lee, S.-Y.; Yang, B.-H.; Lu, J.-J. Rapid Identification and Susceptibility Testing Using the VITEK 2 System Using Culture Fluids from Positive BacT/ALERT Blood Cultures. J. Microbiol. Immunol. Infect. 2008, 41, 259–264.

16. Viasus, D.; Puerta-Alcalde, P.; Cardozo, C.; Suárez-Lledó, M.; Rodríguez-Nuñez, O.; Morata, L.; Feheir, C.; Marco, F.; Chumbita, M.; Moreno-Garcia, E.; et al. Predictors of Multidrug-Resistant Pseudomonas Aeruginosa in Neutropenic Patients with Bloodstream Infection. Clin. Microbiol. Infect. 2020, 26, 345–350. [CrossRef]

17. Vazquez-Guillamet, M.C.; Vazquez, R.; Mikec, S.T.; Kollef, M.H. Predicting Resistance to Piperacillin-Tazobactam, Cefepime and Meropenem in Septic Patients with Bloodstream Infection Due to Gram-Negative Bacteria. Clin. Infect. Dis. 2017, 65, 1607–1614. [CrossRef]

18. Chen, I.-L.; Lee, C.-H.; Ting, S.-W.; Wang, L.Y.-C. Prediction of Imipenem-Resistant Microorganisms among the Nosocomial Critically Ill Patients with Gram-Negative Bacilli Septicemia: A Simple Risk Score. Infect. Drug Resist. 2018, 11, 283–293. [CrossRef]

19. Giannella, M.; Freire, M.; Rinaldi, M.; Abdala, M.; Rubin, A.; Mularoni, A.; Gruttadauria, S.; Grossi, P.; Shbaklo, N.; Tandoi, F.; et al. Development of a Risk Prediction Model for Carbapenem-Resistant Enterobacteriaceae Infection after Liver Transplantation: A Multinational Cohort Study. Clin. Infect. Dis. 2021, 73, e695–e706. [CrossRef]

20. Giannella, M.; Bartoletti, M.; Campoli, C.; Rinaldi, M.; Coladonato, S.; Pascale, R.; Tedeschi, S.; Ambretti, S.; Cristini, F.; Tumietto, F.; et al. Impact of Carbapenemase-Producing Enterobacteriaceae Colonization on Infection Risk after Liver Transplantation: A Prospective Observational Cohort Study. Clin. Microbiol. Infect. 2019, 25, 1525–1531. [CrossRef]

21. Falcone, M.; Tiseo, G.; Dentali, F.; La Regina, M.; Foglia, E.; Gambacorta, M.; Garagliola, E.; Bonardi, G.; Clerici, P.; Colombo, F.; et al. Predicting Resistant Etiology in Hospitalized Patients with Blood Cultures Positive for Gram-Negative Bacilli. Eur. J. Intern. Med. 2018, 53, 21–28. [CrossRef]

22. Tumbarello, M.; Trecarichi, E.M.; Tumietto, F.; Del Bono, V.; De Rosa, F.G.; Bassetti, M.; Losito, A.R.; Tedeschi, S.; Saffioti, C.; Corcione, S.; et al. Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2014, 58, 3514–3520. [CrossRef]

23. Giannella, M.; Trecarichi, E.M.; De Rosa, F.G.; Del Bono, V.; Bassetti, M.; Lewis, R.E.; Losito, A.R.; Corcione, S.; Saffioti, C.; Bartoletti, M.; et al. Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infection among Rectal Carriers: A Prospective Observational Multicentre Study. Clin. Microbiol. Infect. 2014, 20, 1357–1362. [CrossRef]

24. World Health Organization Regional Office for Europe and European Centre for Disease Prevention and Control. Surveillance of Antimicrobial Resistance in Europe, 2020 Data; Executive Summary; WHO Regional Office for Europe: Copenhagen, Denmark, 2021. Available online: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2020 (accessed on 6 June 2022).

25. European Centre for Disease Prevention and Control. Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epi-Demiological Report 2019; ECDC: Stockholm, Sweden, 2020. Available online: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2019 (accessed on 6 June 2022).

26. Vasudevan, A.; Mukhopadhyay, A.; Li, J.; Yuen, E.G.Y.; Tambyah, P.A. A Prediction Tool for Nosocomial Multi-Drug Resistant Gram-Negative Bacilli Infections in Critically Ill Patients: A Retrospective Case-Control Study. J. Glob. Antimicrob. Resist. 2020, 22, 826–831. [CrossRef]
28. European Centre for Disease Prevention and Control. *Surveillance of Healthcare-Associated Infections and Prevention Indicators in European Intensive Care Units: HAI Net ICU Protocol, Version 2.2*. ECDC: Stockholm, Sweden, 2017. Available online: https://www.ecdc.europa.eu/en/publications-data/surveillance-healthcare-associated-infections-and-prevention-indicators-european (accessed on 6 June 2022).

29. Horan, T.C.; Andrus, M.; Dudeck, M.A. CDC/NHSN Surveillance Definition of Health Care-Associated Infection and Criteria for Specific Types of Infections in the Acute Care Setting. *Am. J. Infect. Control* 2008, 36, 309–332. [CrossRef]

30. Salmanov, A.; Litus, V.; Vdovychenko, S.; Litus, O.; Davtian, L.; Ubogov, S.; Bisyuk, Y.; Drozdova, A.; Vlasenko, I. Healthcare-associated infections in intensive care units. *Wiadomosci Lek.* 2019, 72, 963–969. [CrossRef]

31. Knaus, W.A.; Draper, E.A.; Wagner, D.P.; Zimmerman, J.E. APACHE II: A Severity of Disease Classification System. *Crit. Care Med.* 1985, 13, 818–829. [CrossRef]

32. Le Gall, J.-R.; Lemeshow, S.; Saulnier, F. A New Simplified Acute Physiology Score (SAPS II) Based on a European/North American Multicenter Study. *JAMA* 1993, 270, 2957–2963. [CrossRef]

33. Vincent, J.L.; Moreno, R.; Takala, J.; Willatts, S.; De Mendonça, A.; Bruining, H.; Reinhart, C.K.; Suter, P.M.; Thijs, L.G. The SOFA (Sepsis-Related Organ Failure Assessment) Score to Describe Organ Dysfunction/Failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med.* 1996, 22, 707–710. [CrossRef]

34. Charlson, M.; Pompei, P.; Ales, K.; MacKenzie, C. A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation. *J. Chronic Dis.* 1987, 40, 373–383. [CrossRef]

35. Curtoni, A.; Cipriani, R.; Marra, E.; Barbui, A.; Cavallo, R.; Costa, C. Rapid Identification of Microorganisms from Positive Blood Culture by MALDI-TOF MS After Short-Term Incubation on Solid Medium. *Curr. Microbiol.* 2017, 74, 97–102. [CrossRef]

36. EUCAST: Clinical Breakpoints and Dosing of Antibiotics. Available online: https://www.eucast.org/clinical_breakpoints/ (accessed on 19 June 2022).

37. Vincent, J.L.; Sakr, Y.; Singer, M.; Martin-Loeches, I.; Machado, F.R.; Marshall, J.C.; Finfer, S.; Pelosi, P.; Brazzi, L.; Aditianingsih, D.; et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. *JAMA* 2020, 323, 1478–1487. [CrossRef][PubMed]

38. Jarlier, V.; Diaz Högb erg, L.; Heuer, O.E.; Campos, I.; Eckmanns, T.; Giske, C.G.; Grundmann, H.; Johnson, A.P.; Kahlmeter, G.; Monen, J.; et al. Strong Correlation between the Rates of Intrinsically Antibiotic-Resistant Species and the Rates of Acquired Resistance in Gram-Negative Species Causing Bacteremia, EU/EEA, 2016. *Eurosurveillance* 2019, 24, 1800538. [CrossRef][PubMed]

39. Giannella, M.; Bussini, L.; Pascale, R.; Bartoletti, M.; Malagrino, M.; Pancaldi, L.; Toschi, A.; Ferraro, G.; Marconi, L.; Ambretti, S.; et al. Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients with Gram-Negative bloodstream Infections. *Open Forum Infect. Dis.* 2019, 6, ofz505. [CrossRef][PubMed]

40. Dickstein, Y.; Edelman, R.; Dror, T.; Hussein, K.; Bar-Lavie, Y.; Paul, M. Carbapenem-Resistant *Enterobacteriaceae* Colonization and Infection in Critically Ill Patients: A Retrospective Matched Cohort Comparison with Non-Carriers. *J. Hosp. Infect.* 2016, 94, 54–59. [CrossRef]

41. Tuon, F.F.; Rocha, J.L.; Toledo, P.; Arend, L.N.; Dias, C.H.; Leite, T.M.; Penteado-Filho, S.R.; Pilonetto, M.; Zavascki, A.P. Risk Factors for KPC-Producing * Klebsiella pneumoniae* Bacteremia. *Braz. J. Infect. Dis.* 2012, 16, 416–419. [CrossRef]

42. Cano, A.; Gutiérrez-Gutiérrez, B.; Machuca, I.; Gracia-Ahuftinger, I.; Pérez-Nadales, E.; Causse, M.; Castón, J.J.; Guzman-Puche, J.; Torre-Giménez, J.; Kindelán, L.; et al. Risks of Infection and Mortality Among Patients Colonized with * Klebsiella pneumoniae* Carbenemase-Producing K. *Pneumoniae*: Validation of Scores and Proposal for Management. *Clin. Infect. Dis.* 2018, 66, 1204–1210. [CrossRef]

43. McCann, E.; Srinivasan, A.; DeRyke, C.A.; Ye, G.; DePestel, D.D.; Murray, J.; Gupta, V. Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study. *Open Forum Infect. Dis.* 2018, 5, ofy241. [CrossRef]

44. Qin, X.; Wu, S.; Hao, M.; Zhu, J.; Ding, B.; Yang, Y.; Xu, X.; Wang, M.; Yang, F.; Hu, F. The Colonization of Carbapenem-Resistant *Klebsiella pneumoniae*: Epidemiology, Resistance Mechanisms, and Risk Factors in Patients Admitted to Intensive Care Units in China. *J. Infect. Dis.* 2020, 221, S206–S214. [CrossRef]

45. Montrucchio, G.; Corecione, S.; Sales, G.; Curtoni, A.; De Rosa, F.G.; Brazzi, L. Carbapenem-Resistant *Klebsiella pneumoniae* in ICU-Admitted COVID-19 Patients: Keep an Eye on the Ball. *J. Glob. Antimicrob. Resist.* 2020, 23, 398–400. [CrossRef]

46. Harris, A.D.; Jackson, S.S.; Robinson, G.; Pineles, L.; Thom, K.A.; Wang, Y.; Doll, M.; Pettigrew, M.M.; Johnson, J.K. * Pseudomonas aeruginosa* Colonization in the Intensive Care Unit: Prevalence, Risk Factors, and Clinical Outcomes. *Infect. Control Hosp. Epidemiol.* 2016, 37, 544–548. [CrossRef]

47. Cohen, R.; Babushkin, F.; Cohen, S.; Afraimov, M.; Shapiro, M.; Uda, M.; Khabra, E.; Adler, A.; Ben Ami, R.; Paikin, S. A Prospective Survey of *Pseudomonas aeruginosa* Colonization and Infection in the Intensive Care Unit. *Antimicrob. Resist. Infect. Control* 2017, 6, 7. [CrossRef]

48. Falagas, M.E.; Kopterides, P. Risk Factors for the Isolation of Multi-Drug-Resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa*: A Systematic Review of the Literature. *J. Hosp. Infect.* 2006, 64, 7–15. [CrossRef]

49. Huh, K.; Chung, D.R.; Ha, Y.E.; Ko, J.-H.; Kim, S.-H.; Kim, M.-J.; Huh, H.J.; Lee, N.Y.; Cho, S.Y.; Kang, C.-I.; et al. Impact of Difficult-to-Treat Resistance in Gram-Negative Bacteremia on Mortality: Retrospective Analysis of Nationwide Surveillance Data. *Clin. Infect. Dis.* 2020, 71, e487–e496. [CrossRef]
50. Tumbarello, M.; Viale, P.; Viscoli, C.; Trecarichi, E.M.; Tumietto, F.; Marchese, A.; Spanu, T.; Ambretti, S.; Ginocchio, F.; Cristini, F.; et al. Predictors of Mortality in Bloodstream Infections Caused by *Klebsiella pneumoniae* Carbapenemase-Producing *K. pneumoniae*: Importance of Combination Therapy. *Clin. Infect. Dis.* 2012, 55, 943–950. [CrossRef]

51. Bartoletti, M.; Giannella, M.; Lewis, R.; Caraceni, P.; Tedeschi, S.; Paul, M.; Schramm, C.; Bruns, T.; Merli, M.; Cobos-Trigueros, N.; et al. A Prospective Multicentre Study of the Epidemiology and Outcomes of Bloodstream Infection in Cirrhotic Patients. *Clin. Microbiol. Infect.* 2018, 24, 546.e1–546.e8. [CrossRef]

52. Ben-David, D.; Kordevani, R.; Keller, N.; Tal, I.; Marzel, A.; Gal-Mor, O.; Maor, Y.; Rahav, G. Outcome of Carbapenem Resistant *Klebsiella pneumoniae* Bloodstream Infections. *Clin. Microbiol. Infect.* 2012, 18, 54–60. [CrossRef]

53. Montrucchio, G.; Sales, G.; Corcione, S.; De Rosa, F.G.; Brazzi, L. Choosing Wisely: What Is the Actual Role of Antimicrobial Stewardship in Intensive Care Units? *Minerva Anestesiol.* 2019, 85, 71–82. [CrossRef]

54. De Rosa, F.G.; Corcione, S.; Montrucchio, G.; Brazzi, L.; Di Perri, G. Appropriate Treatment of Invasive Candidiasis in ICU: Timing, Colonization Index, Candida Score & Biomarkers, Towards de-Escalation? *Turk. J. Anaesthesiol. Reanim.* 2016, 44, 279–282. [CrossRef]

55. Kang, C.-I.; Kim, S.-H.; Park, W.B.; Lee, K.-D.; Kim, H.-B.; Kim, E.-C.; Oh, M.-D.; Choe, K.-W. Bloodstream Infections Caused by Antibiotic-Resistant Gram-Negative Bacilli: Risk Factors for Mortality and Impact of Inappropriate Initial Antimicrobial Therapy on Outcome. *Antimicrob. Agents Chemother.* 2005, 49, 760–766. [CrossRef]